

Indivior Publications 2015

Manuscripts

Early-Stage Discovery and Development

1. Ashby C, Rice O, Heidbreder C, Gardner E. The selective dopamine D3 receptor antagonist SB-277011A attenuates drug- or food deprivation reactivation of expression of conditioned place preference for cocaine in male Sprague-Dawley rats. *Synapse* 2015;69(6):336-345. <http://dx.doi.org/10.1002/syn.21820>
2. Ashby C, Rice O, Heidbreder C, Gardner E. The selective dopamine D3 receptor antagonist SB-277011A significantly accelerates extinction to environmental cues associated with cocaine-induced place preference in male Sprague-Dawley rats. *Synapse*. 2015;69(10):512-514. <http://dx.doi.org/10.1002/syn.21839>

Treatment of Schizophrenia

1. Laffont CM, Gomeni R, Zheng B, Heidbreder C, Fudala PJ, Nasser AF. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone. *Clin Pharmacol*. 2015;55(1):93-103. <http://dx.doi.org/10.1002/jcph.366>

Treatment of Opioid Use Disorder

1. Nasser A, Heidbreder C, Liu Y, Fudala PJ. Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers. *Clin Pharmacokin*. 2015;54(8): 837-849. <http://dx.doi.org/10.1007/s40262-015-0238-6>

White Papers

1. Heidbreder C, Johnson RE, Chapleo C, Fudala PJ. Indivior: Pioneering research and development in the treatment of addictions. *Nature*. 2015;522(7557):S45-S63. <http://www.nature.com/nature/outlook/addiction/pdf/Indivior.pdf>

Abstracts

Treatment of Opioid Use Disorder

1. Jones JP III, Liu Y, Fudala PJ, Heidbreder C, Nasser A. The effect of hepatic impairment (HI) or HCV infection on the pharmacokinetics (PK) of buprenorphine and naloxone. Proceedings of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). Abstract: #15-A-599-ASCPT. New Orleans, LA; March 3-7, 2015.
2. Jia H, Greenwald MK, Vince B, Fudala PJ, Heidbreder C, Nasser A. A multiple-dose study of blockade of opioid subjective effects by subcutaneous injections of depot buprenorphine in subjects with opioid use disorder. Proceedings of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). Abstract: #15-A-554-ASCPT. New Orleans, LA; March 3-7, 2015.

Treatment of Schizophrenia

1. Jones JP III, Fudala PJ, Heidebreder C, Nasser A. Modeling and simulation to evaluate possible consequences of dose dumping for RBP-7000, a new sustained-release formulation of risperidone (Ris). Proceedings of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). Abstract: #15-A-818-ASCPT. New Orleans, LA. March 3-7, 2015.